MedTrace Logo

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

NCT00423683 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2016-06-08

Study results available
· View outcomes & findings →

Summary

The development of clots is a potentially deadly complication in many cancer patients. The current optimal treatment is unknown. Evidence supporting the effectiveness of the use of Inferior Vena Caval Filters is lacking. This study will compare the two standard of care treatment options: anticoagulation with or without a inferior vena cava filter. The anticoagulation medication chosen will be Arixtra and it will be given once a day as an injection. Patients will be called at various intervals to monitor their signs and symptoms of new thromboembolisms.

Conditions

Interventions

DRUG

Arixtra alone

Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)

DEVICE

Arixtra + filter

Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.

Sponsors & Collaborators

Principal Investigators

  • Myra Barginear, MD · North Shore University Hospital Monter Cancer Center

  • Daniel R. Budman, MD · North Shore University Hospital Monter Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423683 on ClinicalTrials.gov